Sign up to save your podcasts
Or
Share Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.
Click here to read the full article
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet GroupShun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.
Click here to read the full article
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet in conversation with
View all
JAMA Editors' Summary
134 Listeners
The Lancet Voice
22 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
3 Listeners
The Lancet Oncology in conversation with
1 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
1 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
1 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
eBioMedicine in conversation with
0 Listeners
In conversation with...
0 Listeners
News Connect あなたと経済をつなぐ5分間 #ニュースコネクト
21 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners
The Lancet Primary Care in conversation with
0 Listeners
The Lancet Regional Health Americas in conversation with
0 Listeners